If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Forteo ® (teriparatide injection)
20-mcg daily dose in a 2.4-mL prefilled delivery device
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
What are the approved indications for FORTEO® (teriparatide injection)?
Forteo (teriparatide injection) is indicated for the treatment of postmenopausal women with osteoporosis at high risk of fracture, increase of bone mass in men with primary or hypogonadal osteoporosis, and glucocorticoid-induced osteoporosis.
Teriparatide was approved by the Food and Drug Administration on November 26, 2002.1
Teriparatide is indicated for
- the treatment of postmenopausal women with osteoporosis at high risk for fracture (defined herein as having a history of osteoporotic fracture or multiple risk factors for fracture) or who have failed or are intolerant to other available osteoporosis therapy,
- increase of bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture or who have failed or are intolerant to other available osteoporosis therapy, and
- treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy (daily dosage equivalent to 5 mg or greater of prednisone) at high risk for fracture or who have failed or are intolerant to other available osteoporosis therapy.2
In postmenopausal women with osteoporosis, teriparatide reduces the risk of vertebral and nonvertebral fractures.2
Enclosed Prescribing Information
1Food and Drug Administration (FDA). Drug approval package: Forteo [teriparatide (rDNA origin)] Injection. November 26, 2002. Accessed May 22, 2023. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2002/21-318_Forteo.cfm
2Forteo [package insert]. Indianapolis, IN: Eli Lilly and Company; 2021.
Date of Last Review: May 04, 2023